clevidipine
Sign in to saveClevidipine (INN, trade name Cleviprex) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Clevidipine is used IV only and practitioners titrate this drug to lower blood pressure. It has a half-life of approximately one minute. It is rapidly inactivated by esterases.
Research
210 papers- Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Hemorrhagic Stroke.Neurocritical care · 2022
- The Current Role of Clevidipine in the Management of Hypertension.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
- Clevidipine.Drugs in R&D · 2002
- Comparison between clevidipine and nicardipine in cerebrovascular diseases: A systematic review and meta-analysis.Clinical neurology and neurosurgery · 2023
- Clevidipine for the management of hypertension in the perioperative cardiac and noncardiac surgical settings: a systematic review.Frontiers in medicine · 2025
via PubMed
Article
10 sectionsContents
- Basic chemical and pharmacological properties
- Stereochemistry
- Dosage and administration
- Safety information
- Drug interactions
- Storage
- Phase III clinical trial results
- References
- Further reading
- External links
Clevidipine (INN, trade name Cleviprex) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Clevidipine is used IV only and practitioners titrate this drug to lower blood pressure. It has a half-life of approximately one minute. It is rapidly inactivated by esterases.
It was approved by the United States Food and Drug Administration on August 1, 2008.